T1	Participants 37 61	Wegener's granulomatosis
T2	Participants 333 457	trial at eight centers to evaluate etanercept for the maintenance of remission in 180 patients with Wegener's granulomatosis
T3	Participants 969 1138	Of the 174 patients who could be evaluated, 126 (72.4 percent) had a sustained remission, but only 86 (49.4 percent) remained in remission for the remainder of the trial
#1	AnnotatorNotes T3	only 174 were evaluable 
